Abstract: A trust rule between a first service and a second service in a plurality of services deployed in a distributed system is received; the trust rule defines whether the first service is allowed to access the second service. A trust tree is obtained for the distributed system, and the trust tree comprises a plurality of certificates for accessing the plurality of services. A first group of certificates is selected for the first service based on the trust rule and the trust tree, and the first group of certificates enables the first service to access the second service.

Abstract: A battery module includes: a plurality of cells; and a cell restraining structure having an internal frame and an external shell fit with the internal frame to form a plurality of chambers for receiving the plurality of cells respectively so as to package and manage the cells. The internal frame includes an elastic element forming at least one first surface of each chamber, the elastic element being elastically deformed as being pressed by a predetermined amount by a corresponding cell received in each chamber such that the elastically deformed elastic element exerts a first force to the corresponding cell. The elastically deformed elastic element is further pressed or tends to recover in responding to reversible expansion or contraction of the corresponding cell in operation such that a restraining force to the corresponding cell is determined by the first force.

Abstract: Disclosed are flexible glass and a preparation method therefor; weight proportions of the raw materials used in the flexible glass are: 60.04-63.01 parts silicon dioxide, 16.7-21.5 parts aluminum oxide, 12.93-19.85 parts boron oxide, 2.43-14.19 parts calcium carbonate, 0.16-2.07 parts magnesium oxide. 0.5-2.74 parts strontium carbonate and 0-4.16 parts barium nitrate. The method includes: step 1: pouring raw materials into a mixer, and uniformly mixing to form a mixture; step 2: adding the mixture into a glass furnace, heating to melt the glass, and the melted glass entering a platinum feeding channel for clarification and flowing into a tube drawing tunnel; step 3: drawing the liquid glass into a long glass tube; step 4: using a laser cutting machine to transversely and longitudinally cut the glass tube according to specification requirements, forming a glass sheet; step 5: inspecting the glass sheet, and preparing a flexible glass product.

Abstract: Disclosed are electronic glass having high liquidus viscosity and a preparation method. The proportions of the raw materials used in the electronic glass are: SiO2: 65.56-68.6%; Al2O3: 10.58-14%; B2O3: 7-11%; SrO: 0.27-3.26%; BaO: 7.20-10.12%; CaO: 0.22-1.22%; MgO: 0-1.05%; MgO+CaO+SrO+BaO<13%; and the liquidus viscosity of the electronic glass is greater than 200,000 poise. The minimum value of the temperature corresponding to a liquidus temperature reduction of 100,000 poise in the electronic glass is 22° C. The electronic glass has a strain point temperature of 670-739° C., a Young's modulus of 70-83 GPa, and a density of 2.38-2.45 g/cm3, the liquidus viscosity is ensured to be higher than 200,000 poise, the electronic glass is well suited to overflow downdraw forming, and a relatively low density value can be obtained.

Abstract: This application relates to the field of lighting, and discloses an LED filament. The LED filament includes an LED chip unit, a light conversion layer, and an electrode. The light conversion layer covers the LED chip unit and part of the electrode, and a color of a light emitted by the LED filament after lighting is different from a color of the light conversion layer. This application has the characteristics of uniform light emission and good heat dissipation effect.

Abstract: A method for determining causes of network slice performance degradation in an open radio access network (O-RAN), the O-RAN being under Central Unit-Distributed Unit (CU-DU) functional split. In a setup phase, telemetries that contain multivariate observations of DUs are obtained, telemetry data is aggregated, high order features from correlations between multivariate observations across the DUs is extracted for a specific time slot, and a k-time slots ahead performance model is learned. In a detection phase, the performance model forecasts the network slice performance upon receiving new telemetries. If a performance degradation is forecasted, a set of performance models is sampled and impact scores based on gradients of telemetries are computed. The high order features using the sampled performance prediction models are extracted.

Abstract: A tandem photovoltaic device includes: a tunnel junction between an upper cell unit and a lower cell unit. The lower cell unit is a crystalline silicon cell. The tunnel junction includes: a carrier transport layer, a crystalline silicon layer, and an intermediate layer located between the carrier transport layer and the crystalline silicon layer. The carrier transport layer is a metal oxide layer. The intermediate layer includes a tunneling layer. The crystalline silicon layer has a doping concentration greater than or equal to 1017 cm?3. The carrier transport layer is in direct contact with a shadow surface of the upper cell unit. If the crystalline silicon layer is a p-type crystalline silicon layer, a first energy level is close to a second energy level. If the crystalline silicon layer is an n-type crystalline silicon layer, a third energy level is close to a fourth energy level.

Abstract: The present disclosure relates to the field of photovoltaic technologies. Disclosed are a solar cell and a photovoltaic module. The solar cell includes: an absorption layer; and an energy selective contact layer located on a surface of the absorption layer, the energy selective contact layer having selectivity for electron energy or hole energy, and the material of the energy selective contact layer including a low-dimensional perovskite material. According to the solar cell and the photovoltaic module provided by the present disclosure, a photovoltaic module can be manufactured.

Abstract: A well cementing method is described for improving cementing quality by controlling the hydration heat of cement slurry. By controlling the degree and/or rate of hydration heat release from cement slurry, the method improves the hydration heat release during formation of cement with curing of cement slurry, improves the binding quality between the cement and the interfaces, and in turn improves the cementing quality at the open hole section and/or the overlap section. The cementing method improves cementing quality of oil and gas wells and reduces the risk of annular pressure.

Abstract: Provided are a display panel, a method for driving a display panel, and a display device. The display panel includes first pixels. The first pixel includes first and second light-emitting elements, and first and second pixel circuits respectively electrically connected to first electrodes of the first and second light-emitting elements. First electrodes of the first and second light-emitting element are independent from each other. Second electrodes of the first and second light-emitting elements are electrically connected to each other. Light-emitting material layers of the first and second light-emitting elements are formed into one piece. When the display panel displays at least one frame of an image, data voltages received by the first pixel circuit and the second pixel circuit in a same first pixel are different from each other. Thus, an influence of hysteresis effect on brightness of the first pixel is reduced to improve the display effect.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSID).

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSHD).

Abstract: A machine-learning method to optimize resource allocation extracts human-interpretable (e.g., doctor-interpretable) entity profiles from a text-labeled data graph of a system having a plurality of entities. The data graph is associated with a smart hospital and includes nodes representing the entities and edges between the nodes representing links between the entities. The method includes: obtaining the data graph and extracting the human-interpretable entity profiles from a tensor that has been learned, using a neural network, to capture patterns among text associated with the edges between respective pairs of the nodes. The neural network layers of the neural network are constructed such that the edges are modeled as a function of the associated text and cluster representations of the respective pairs of the nodes.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSHD).

Abstract: A method extracts human-interpretable entity profiles from a text-labeled data graph of a system having a plurality of entities. The data graph includes nodes representing the entities and edges between the nodes representing links between the entities. A plurality of text is respectively associated with the corresponding edges. The method includes: constructing neural network layers configured such that each of the edges between a pair of the nodes is modeled as a function of the associated text and cluster representations of the pair of the nodes; for each one of the pair of nodes, performing machine learning to learn a tensor to capture patterns among the associated text and the pair of nodes, and extracting the entity profiles from the tensor.

Abstract: A method provides a trustworthy artificial intelligence graph-based solution for configuring a plurality of systems in a network. The method includes generating a graph in which each node in the graph represents one of the plurality of systems, wherein links are created between the nodes in the graph, and passing messages along the links. Each node passes a message and a level of uncertainty in the message to neighboring nodes of each node, and receives subsequent messages and subsequent levels of uncertainty in the subsequent messages from the neighboring nodes. The method also includes updating, by each node based on the subsequent messages and the subsequent levels of uncertainty in the subsequent messages received from the neighboring nodes, the respective message and the respective level of uncertainty in the respective message, and predicting configuration values for the systems based on the updated messages and the updated levels of uncertainty.

Abstract: An image processing method includes analyzing multiple images data based on Illumination-invariant Feature Network (IF-NET) with an image processing device to generate corresponding sets of eigenvector, in which image data includes a first image data related to at least one first feature of the sets of eigenvector, and a second image data related to at least one second feature of the sets of eigenvector; choosing a corresponding first training set of tiles and second training set of tiles from the first image data and second image data with an image processing device based on IF-NET, and computing on both training set of tiles to generate a least one loss value; and adjusting IF-NET based on a least one loss value. An image processing system is also disclosed herein.

Abstract: Provided are a chimeric antigen receptor, a construction method therefor and an application thereof. The chimeric antigen receptor consists of an antigen binding domain, an extracellular hinge region, a transmembrane domain, a co-stimulatory domain and a CD3z signaling domain. Further provided is a CAR-T cell which comprises two chimeric antigen receptors containing different antigen binding domains, and which is bispecific and exhibits increased cell killing efficiency and a better tumor inhibitory effect in vivo.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression. Also disclosed are pharmaceutical compositions that include XDH RNAi agents and methods of use thereof. The XDH RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the XDH RNAi agents in vivo provides for inhibition of XDH gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by XDH gene expression, such as gout and hyperuricemia.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression. Also disclosed are pharmaceutical compositions that include XDH RNAi agents and methods of use thereof. The XDH RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the XDH RNAi agents in vivo provides for inhibition of XDH gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by XDH gene expression, such as gout and hyperuricemia.